A Phase 3 interventional study of Undiluted I.V.-Hepabig inj(GC5103) and Diluted I.V.-Hepabig inj(GC5103) in Hepatitis B, sponsored by GC Biopharma Corp. Recruiting at 8 sites in South Korea. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-06-25.
Sponsored by GC Biopharma Corp · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Hepatitis B with a site in Korea, Republic of — 3 open to participants now, 6 under way, 1 of them phase 3. Hepatitis B · Korea, Republic of.
Among the 76 studies in Hepatitis B with a site in Korea, Republic of, this one is the 25th largest by planned enrollment of the 70 interventional ones that give a count, is one of 3 that started in 2023, is one of 13 in phase 3, and was the 70th registered.
1,048 studies on the registry are indexed under Hepatitis B; 141 are open to participants now.
Browse Hepatitis B studies →3 of the 76 studies in Hepatitis B with a site in Korea, Republic of are open now. Recruiting first, the newest first:
GigaGen, Inc. · Sites in Korea, Republic of, United States, Australia and 2 more countries
Ages 18+
Seoul St. Mary's Hospital · Sites in Korea, Republic of
Ages 19–70
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 31 · Phase 3 15 · Phase 4 8
First in 2002; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 105 is below the median of 145 across 758 interventional studies indexed under Hepatitis B.
Median enrollment 80 across the 70 interventional studies, 600 across the 3 observational. Of the 64 that completed or were terminated, 25 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 76 have an industry lead sponsor. The 10 most frequent:
This study is registered under GC Biopharma Corp, one of the names counted as GC Biopharma Corp.. Under that name alone:
GC Biopharma Corp is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
GC Biopharma Corp. has 5 studies filed under Hepatitis B — fewer than ten, so there is no comparison to draw.
2 of the studies in Hepatitis B with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06963710Aligos TherapeuticsA Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | 2027-03 |
| NCT06537414GlaxoSmithKlineA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 76 studies in Hepatitis B with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous infusion of I.V.-Hepabig inj. in post-liver transplant patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Undiluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit within approximately 30 minutes
Biological: Undiluted I.V.-Hepabig inj(GC5103)
Diluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit into Dextrose 5% in water within approximately 1 hour
Biological: Diluted I.V.-Hepabig inj(GC5103)
undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
Adverse events occurred during clinical trials
Safety will be assessed throughout the study through clinical safety evaluations(Adverse events)
Time frame: during 20 weeks post first Investigational product administration
Positive rate of Hepatitis B Surface Antigen(HBsAg)
Hepatitis B Surface Antigen(HBsAg) will be tested at every visit(V1\~V7)
Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks
Hepatitis B Surface Antibody(Anti HBs) titer
Hepatitis B Surface Antibody(Anti HBs) titer will be tested at every visit(V1\~V7)
Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks
Positive rate of Hepatitis B e Antigen(HBeAg)
Hepatitis B e Antigen(HBeAg) will be tested at every visit(V1\~V7)
Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks
Positive rate of Hepatitis B Virus DNA(HBV DNA)
Hepatitis B Virus DNA(HBV DNA) will be tested at every visit(V1\~V7)
Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks
Laboratory tests
Change from baseline in safety laboratory tests results (hematology,chemistry, urine) (each visit)
Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks
Vital signs
Change from baseline in vital sign (Blood Pressure, Pulse Rate, Body Temperature) (each visit)
Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks
Physical examination
Change from baseline in physical examination (Appearance, Skin, Head/Neck, Thorax/Lungs etc) (each visit)
Time frame: Screening, 0, 4, 8, 12, 16, and 20 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Jun 2026, 38 months after the start.
Of 42 industry-sponsored phase 3 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 38 months is above that.
Counting every sponsor, half of 50 studies reached it within 15 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.